Serina Therapeutics, Inc. (SER) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
601 GENOME WAY HUNTSVILLE, AL 35806 |
| State of Incorp. | AL |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 6,041 | 4,267 | 3,672 | 3,185 | 6,064 | 8,706 | |||
| Cash and cash equivalent | 6,041 | 4,267 | 3,672 | 3,185 | 6,064 | 8,706 | |||
| Receivables | 14 | 51 | 65 | ||||||
| Prepaid expense | 773 | 337 | 594 | 747 | 800 | ||||
| Other current assets | 177 | 150 | 77 | 143 | 2 | ||||
| Other undisclosed current assets | 1,000 | 1,000 | 1,333 | 1,334 | 2,000 | 166 | |||
| Total current assets: | 7,991 | 5,754 | 5,676 | 5,423 | 8,917 | 8,937 | |||
| Noncurrent Assets | |||||||||
| Finance lease, right-of-use asset, after accumulated amortization | 81 | 86 | 92 | 98 | 104 | ||||
| Operating lease, right-of-use asset | 362 | 412 | 461 | 509 | 562 | 627 | |||
| Property, plant and equipment | 588 | 484 | 501 | 519 | 540 | 564 | |||
| Intangible assets, net (including goodwill) | 509 | 541 | 574 | ||||||
| Intangible assets, net (excluding goodwill) | 509 | 541 | 574 | ||||||
| Prepaid expense | 333 | ||||||||
| Restricted cash and investments | 50 | 50 | 50 | ||||||
| Total noncurrent assets: | 950 | 977 | 1,048 | 2,012 | 1,791 | 1,919 | |||
| TOTAL ASSETS: | 8,941 | 6,731 | 6,724 | 7,435 | 10,708 | 10,856 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 3,016 | 2,167 | 2,173 | 1,159 | 1,972 | 4,013 | |||
| Accounts payable | 1,706 | 1,188 | 744 | 1,203 | 2,605 | ||||
| Accrued liabilities | 1,310 | 979 | 1,429 | 1,159 | 320 | 1,297 | |||
| Other undisclosed accounts payable and accrued liabilities | 449 | 111 | |||||||
| Debt | 10,463 | 10,456 | 9,770 | ||||||
| Other liabilities | 545 | 185 | 193 | 198 | 5 | ||||
| Other undisclosed current liabilities | 1,694 | 200 | 276 | ||||||
| Total current liabilities: | 3,561 | 2,352 | 2,366 | 13,514 | 12,633 | 14,059 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 693 | 693 | 693 | ||||||
| Long-term debt, excluding current maturities | 693 | 693 | 693 | ||||||
| Liabilities, other than long-term debt | 185 | 227 | 268 | 312 | 362 | 413 | |||
| Operating lease, liability | 185 | 227 | 268 | 312 | 362 | 413 | |||
| Other undisclosed noncurrent liabilities | 3,549 | 2,593 | 3,582 | 6,744 | 13,413 | ||||
| Total noncurrent liabilities: | 3,734 | 2,820 | 3,850 | 7,749 | 14,468 | 1,106 | |||
| Total liabilities: | 7,295 | 5,172 | 6,216 | 21,263 | 27,101 | 15,165 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 1,802 | 1,701 | 641 | (13,774) | (16,363) | (4,309) | |||
| Preferred stock | 4,940 | ||||||||
| Common stock | 1 | 1 | 1 | 1 | 1 | 1 | |||
| Common stock held by subsidiary | (250) | (250) | |||||||
| Additional paid in capital | 52,440 | 50,831 | 44,958 | 8,000 | 6,821 | 1,125 | |||
| Accumulated other comprehensive loss | |||||||||
| Accumulated deficit | (55,579) | (49,131) | (44,318) | (21,775) | (23,185) | (5,435) | |||
| Other undisclosed equity, attributable to parent | 250 | 250 | |||||||
| Equity, attributable to noncontrolling interest | (156) | (142) | (133) | (54) | (30) | ||||
| Total equity: | 1,646 | 1,559 | 508 | (13,828) | (16,393) | (4,309) | |||
| TOTAL LIABILITIES AND EQUITY: | 8,941 | 6,731 | 6,724 | 7,435 | 10,708 | 10,856 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 130 | (14) | 14 | 51 | 5 | |||
| Gross profit: | 130 | (14) | 14 | 51 | 5 | |||
| Operating expenses | (5,695) | (5,858) | 11,569 | (5,326) | (3,917) | (2,326) | ||
| Operating income (loss): | (5,565) | (5,858) | 11,555 | (5,312) | (3,866) | (2,321) | ||
| Nonoperating income (expense) | (897) | 1,036 | 2,797 | 6,695 | 9,043 | (7,116) | ||
| Interest and debt expense | (9) | (17) | (16) | (242) | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (6,471) | (4,822) | 14,335 | 1,367 | 4,935 | (9,437) | ||
| Other undisclosed loss from continuing operations before income taxes | (16,512) | |||||||
| Income (loss) from continuing operations: | (6,471) | (4,822) | (2,177) | 1,367 | 4,935 | (9,437) | ||
| Other undisclosed net income (loss) | 9 | (575) | 16 | 242 | ||||
| Net income (loss): | (6,462) | (4,822) | (2,752) | 1,383 | 5,177 | (9,437) | ||
| Net income attributable to noncontrolling interest | 14 | 9 | 12 | 27 | 27 | |||
| Net income (loss) attributable to parent: | (6,448) | (4,813) | (2,740) | 1,410 | 5,204 | (9,437) | ||
| Preferred stock dividends and other adjustments | (117) | |||||||
| Undistributed earnings (loss) allocated to participating securities, basic | (9) | (12) | (27) | (27) | ||||
| Other undisclosed net income available to common stockholders, basic | 9 | 12 | 27 | 27 | ||||
| Net income (loss) available to common stockholders, diluted: | (6,565) | (4,813) | (2,740) | 1,410 | 5,204 | (9,437) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2025 Q3 | 6/30/2025 Q2 | 3/31/2025 Q1 | 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (6,462) | (4,822) | (2,752) | 1,383 | 5,177 | (9,437) | ||
| Other undisclosed comprehensive loss | ||||||||
| Comprehensive income (loss): | (6,462) | (4,822) | (2,752) | 1,383 | 5,177 | (9,437) | ||
| Comprehensive income, net of tax, attributable to noncontrolling interest | 14 | 9 | 12 | 27 | 27 | |||
| Comprehensive income (loss), net of tax, attributable to parent: | (6,448) | (4,813) | (2,740) | 1,410 | 5,204 | (9,437) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.